MedTrace Logo

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 740

Last updated 2026-05-08

No results posted yet for this study

Summary

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Conditions

Interventions

DRUG

EIK1001

EIK1001 is a Toll-like receptor 7/8 (TLR 7/8) dual agonist.

DRUG

Pembrolizumab (KEYTRUDA® )

Pembrolizumab is a PD-1 inhibitor.

Sponsors & Collaborators

Principal Investigators

  • Etah Kurland · Eikon Therapeutics

  • Muaz Sadeia · Eikon Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2035-12-31
Completion
2040-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hungary
  • Israel
  • Italy
  • New Zealand
  • Norway
  • Poland
  • Portugal
  • Serbia
  • South Africa
  • South Korea
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06697301 on ClinicalTrials.gov